Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mladen V Tzvetkov

Showing results (1-10 of 72) with videos related to

Pageof 8
Sort By:
Pharmacogenomics|October 25, 2017
OCT1 pharmacogenetics in pain management: is a clinical application within reach?Mladen V Tzvetkov
Pharmacogenomics|November 28, 2013
Polymorphic OCT1: a valid biomarker, but for which drugs?Jürgen Brockmöller, Mladen V Tzvetkov
European Journal of Clinical Pharmacology|January 29, 2008
Pharmacogenetics: data, concepts and tools to improve drug discovery and drug treatmentJürgen Brockmöller, Mladen V Tzvetkov
Journal of Biotechnology|April 1, 2008
Phytate utilization by genetically engineered lysine-producing Corynebacterium glutamicumMladen V Tzvetkov, Wolfgang Liebl
Frontiers in Pharmacology|June 21, 2021
OCT1 Polyspecificity-Friend or Foe?Marleen J Meyer, Mladen V Tzvetkov
Journal of Personalized Medicine|December 15, 2018
Impact of Promoter Polymorphisms on the Transcriptional Regulation of the Organic Cation Transporter OCT1 (SLC22A1)Kristin Bokelmann, Jürgen Brockmöller, Mladen V Tzvetkov
Biochemical Pharmacology|November 30, 2019
Stereoselective cell uptake of adrenergic agonists and antagonists by organic cation transportersOle Jensen, Muhammad Rafehi, Mladen V Tzvetkov, et al.
Biochemical Pharmacology|February 21, 2012
The prototypic pharmacogenetic drug debrisoquine is a substrate of the genetically polymorphic organic cation transporter OCT1Ali R Saadatmand, Sina Tadjerpisheh, Jürgen Brockmöller, et al.
Scientific Reports|September 20, 2024
Individual use of self-medication and other remedies in COVID-19 outpatients in Western-PomeraniaSvea Stüdemann, Eik Schäfer, Klaus Hahnenkamp, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 4, 2025
Substrate-specific inhibition of organic cation transporter 1 revealed using a multisubstrate drug cocktailVincent Rönnpagel, Felix Morof, Sarah Römer, et al.
Pageof 8

Showing results (1-10 of 72) with videos related to

Sort By:
Pageof 8
Pharmacogenomics|October 25, 2017
OCT1 pharmacogenetics in pain management: is a clinical application within reach?Mladen V Tzvetkov
Pharmacogenomics|November 28, 2013
Polymorphic OCT1: a valid biomarker, but for which drugs?Jürgen Brockmöller, Mladen V Tzvetkov
European Journal of Clinical Pharmacology|January 29, 2008
Pharmacogenetics: data, concepts and tools to improve drug discovery and drug treatmentJürgen Brockmöller, Mladen V Tzvetkov
Journal of Biotechnology|April 1, 2008
Phytate utilization by genetically engineered lysine-producing Corynebacterium glutamicumMladen V Tzvetkov, Wolfgang Liebl
Frontiers in Pharmacology|June 21, 2021
OCT1 Polyspecificity-Friend or Foe?Marleen J Meyer, Mladen V Tzvetkov
Journal of Personalized Medicine|December 15, 2018
Impact of Promoter Polymorphisms on the Transcriptional Regulation of the Organic Cation Transporter OCT1 (SLC22A1)Kristin Bokelmann, Jürgen Brockmöller, Mladen V Tzvetkov
Biochemical Pharmacology|November 30, 2019
Stereoselective cell uptake of adrenergic agonists and antagonists by organic cation transportersOle Jensen, Muhammad Rafehi, Mladen V Tzvetkov, et al.
Biochemical Pharmacology|February 21, 2012
The prototypic pharmacogenetic drug debrisoquine is a substrate of the genetically polymorphic organic cation transporter OCT1Ali R Saadatmand, Sina Tadjerpisheh, Jürgen Brockmöller, et al.
Scientific Reports|September 20, 2024
Individual use of self-medication and other remedies in COVID-19 outpatients in Western-PomeraniaSvea Stüdemann, Eik Schäfer, Klaus Hahnenkamp, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 4, 2025
Substrate-specific inhibition of organic cation transporter 1 revealed using a multisubstrate drug cocktailVincent Rönnpagel, Felix Morof, Sarah Römer, et al.
Pageof 8